Company & Sponsor Intelligence
AbbVie
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials5
Recruiting1
Completed4
Countries2
Therapeutic footprint
epilepsyparkinsonsunclassified
Indexed studies
NCT04244175A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
epilepsy · United StatesPHASE2
epilepsy · United StatesPHASE2
NCT02381444Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy
parkinsons · GermanyCOMPLETED
parkinsons · GermanyCOMPLETED
NCT07310290Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
unclassified · United StatesRECRUITING
unclassified · United StatesRECRUITING
NCT03104413A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
unclassified · United StatesPHASE3
unclassified · United StatesPHASE3
NCT03105128A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
unclassified · United StatesPHASE3
unclassified · United StatesPHASE3
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →